UA70914C2 - Вакцина для великої рогатої худоби проти респіраторних патологій, спосіб вакцинації та набір для вакцинації великої рогатої худоби - Google Patents
Вакцина для великої рогатої худоби проти респіраторних патологій, спосіб вакцинації та набір для вакцинації великої рогатої худоби Download PDFInfo
- Publication number
- UA70914C2 UA70914C2 UA99020960A UA99020960A UA70914C2 UA 70914 C2 UA70914 C2 UA 70914C2 UA 99020960 A UA99020960 A UA 99020960A UA 99020960 A UA99020960 A UA 99020960A UA 70914 C2 UA70914 C2 UA 70914C2
- Authority
- UA
- Ukraine
- Prior art keywords
- vaccine
- plasmid
- cattle
- promoter
- items
- Prior art date
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 38
- 244000052769 pathogen Species 0.000 title claims abstract description 7
- 230000000241 respiratory effect Effects 0.000 title abstract description 10
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title abstract description 7
- 239000013612 plasmid Substances 0.000 claims abstract description 80
- 229960005486 vaccine Drugs 0.000 claims abstract description 67
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 238000002255 vaccination Methods 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 241001529453 unidentified herpesvirus Species 0.000 claims description 9
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 6
- 229940124551 recombinant vaccine Drugs 0.000 claims description 6
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 5
- 229940031626 subunit vaccine Drugs 0.000 claims description 5
- 241000712003 Human respirovirus 3 Species 0.000 claims description 4
- 101150013191 E gene Proteins 0.000 claims description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 3
- 210000004292 cytoskeleton Anatomy 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 102100036912 Desmin Human genes 0.000 claims description 2
- 108010044052 Desmin Proteins 0.000 claims description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 claims description 2
- 101710145006 Lysis protein Proteins 0.000 claims description 2
- 241000714474 Rous sarcoma virus Species 0.000 claims description 2
- 210000005045 desmin Anatomy 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 101710117545 C protein Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 5
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 1
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 description 43
- 108091034117 Oligonucleotide Proteins 0.000 description 28
- 238000005516 engineering process Methods 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 238000010276 construction Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 239000012190 activator Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 229930027917 kanamycin Natural products 0.000 description 9
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 9
- 229960000318 kanamycin Drugs 0.000 description 9
- 229930182823 kanamycin A Natural products 0.000 description 9
- 230000007170 pathology Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000711895 Bovine orthopneumovirus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940031346 monovalent vaccine Drugs 0.000 description 3
- 229940031348 multivalent vaccine Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 2
- 241000712005 Bovine respirovirus 3 Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 101150055707 98 gene Proteins 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 101800001603 Capsid protein C Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101800001847 Core protein precursor Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101150082674 E2 gene Proteins 0.000 description 1
- 235000009245 Elaeagnus multiflora Nutrition 0.000 description 1
- 240000000298 Elaeagnus multiflora Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000238558 Eucarida Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 description 1
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 208000034493 Mucous membrane disease Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000287882 Pavo Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 102100023591 Polyphosphoinositide phosphatase Human genes 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101150092210 RE gene Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 101150059448 cdk7 gene Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001463 effect on reproduction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/813—Viral vaccine for bovine species, e.g. cattle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9609403A FR2751229B1 (fr) | 1996-07-19 | 1996-07-19 | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
| PCT/FR1997/001325 WO1998003200A2 (fr) | 1996-07-19 | 1997-07-16 | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA70914C2 true UA70914C2 (uk) | 2004-11-15 |
Family
ID=9494497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99020960A UA70914C2 (uk) | 1996-07-19 | 1997-07-16 | Вакцина для великої рогатої худоби проти респіраторних патологій, спосіб вакцинації та набір для вакцинації великої рогатої худоби |
Country Status (28)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751229B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
| FR2804028B1 (fr) * | 2000-01-21 | 2004-06-04 | Merial Sas | Vaccins adn ameliores pour animaux de rente |
| US20040002472A1 (en) * | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
| US7078388B2 (en) | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| US6852705B2 (en) * | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
| EP1606419A1 (en) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| MXPA06005424A (es) | 2003-11-13 | 2007-01-25 | Univ Georgia Res Found | Metodos para caracterizar virus de enfermedad bursal infecciosa. |
| ATE510928T1 (de) | 2004-02-19 | 2011-06-15 | Univ Alberta | Leptinpromotor-polymorphismen und verwendungen davon |
| HRP20100314T1 (hr) | 2005-04-25 | 2010-08-31 | Merial Ltd. | Cjepivo protiv nipah virusa |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| EP1951751B1 (en) | 2005-11-14 | 2017-11-01 | Merial, Inc. | Gene therapy for renal failure |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| SI2147105T1 (sl) | 2007-05-02 | 2013-08-30 | Merial Limited | DNA-plazmidi z izboljšano ekspresijo in stabilnostjo |
| US20080274137A1 (en) * | 2007-05-02 | 2008-11-06 | Jean Christophe Francis Audonnet | DNA plasmids having improved expression and stability |
| EP3168307B1 (en) | 2008-11-28 | 2020-07-15 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant avian influenza vaccine and uses thereof |
| WO2010115133A2 (en) | 2009-04-03 | 2010-10-07 | Merial Limited | Newcastle disease virus vectored avian vaccines |
| US10633667B2 (en) | 2009-12-28 | 2020-04-28 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant NDV antigen and uses thereof |
| JP5959440B2 (ja) | 2010-01-19 | 2016-08-02 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 病原体の検出および治療のための改変オプソニン |
| US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
| EP3093025B1 (en) | 2010-03-12 | 2018-08-01 | Merial Inc. | Bluetongue virus recombinant vaccines and uses thereof |
| CN103269714B (zh) | 2010-08-31 | 2016-06-29 | 梅里亚有限公司 | 以新城疫病毒为载体的疱疹病毒疫苗 |
| AR084358A1 (es) * | 2010-12-27 | 2013-05-08 | Lilly Co Eli | Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc)) |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| US20140287931A1 (en) | 2011-04-04 | 2014-09-25 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| EP2694677A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| AU2012245395A1 (en) | 2011-04-20 | 2013-11-14 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| JP6407714B2 (ja) | 2011-04-25 | 2018-10-17 | アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド | 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物 |
| MX361804B (es) | 2011-05-27 | 2018-12-17 | Boehringer Ingelheim Animal Health Usa Inc | Vacunas genéticas contra el virus hendra y el virus nipah. |
| US9669085B2 (en) | 2011-06-01 | 2017-06-06 | Merial Inc. | Needle-free administration of PRRSV vaccines |
| US9593160B2 (en) | 2011-07-18 | 2017-03-14 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
| ES2626297T3 (es) | 2011-08-12 | 2017-07-24 | Merial, Inc. | Preservación asistida por vacío de productos biológicos, en particular de vacunas |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| US20130177591A1 (en) | 2012-01-10 | 2013-07-11 | Merial Limited | Lipid Based Adjuvants for DNA Plasmids |
| EP3466443B1 (en) | 2012-02-14 | 2020-12-16 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom |
| US9446117B2 (en) | 2012-02-14 | 2016-09-20 | Merial, Inc. | Rotavirus subunit vaccines and methods of making and use thereof |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| ES2664069T3 (es) | 2012-06-13 | 2018-04-18 | Merial, Inc. | Vacunas contra BTV y AHSV de genoma reordenado |
| CA2879915C (en) | 2012-08-01 | 2022-07-05 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
| US9556419B2 (en) | 2013-03-12 | 2017-01-31 | Merial Inc. | Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof |
| EP2976642A4 (en) | 2013-03-15 | 2016-09-21 | Harvard College | METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT |
| EP3848044A1 (en) | 2013-05-21 | 2021-07-14 | President and Fellows of Harvard College | Engineered heme-binding compositions and uses thereof |
| EP3083658B1 (en) | 2013-12-18 | 2019-05-08 | President and Fellows of Harvard College | Crp capture/detection of gram positive bacteria |
| US10010499B2 (en) | 2014-11-03 | 2018-07-03 | Merial Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| DK3313864T3 (da) | 2015-06-23 | 2021-11-01 | Boehringer Ingelheim Animal Health Usa Inc | Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf |
| CN108289928B (zh) | 2015-08-06 | 2024-09-17 | 哈佛大学校长及研究员协会 | 改进的微生物-结合分子和其用途 |
| WO2017031120A1 (en) | 2015-08-20 | 2017-02-23 | Merial, Inc. | Fcv recombinant vaccines and uses thereof |
| MA43016A (fr) | 2015-09-29 | 2018-08-08 | Merial Inc | Vaccins à particules pseudo-virales (vlp) de parvovirus canin (cpv) et utilisations associées |
| RU2714428C2 (ru) | 2015-11-23 | 2020-02-14 | Мериал, Инк. | Слитые белки fmdv-e2 и их применение |
| TWI760322B (zh) | 2016-01-29 | 2022-04-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 重組腺病毒載體裝載之fmdv疫苗及其用途 |
| CN109021081B (zh) * | 2018-08-10 | 2019-06-04 | 山东大学 | 一种牛病毒性腹泻病毒样颗粒及其构建方法与应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169628A (en) * | 1988-04-22 | 1992-12-08 | The Upjohn Company | Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3 |
| CA2087853A1 (en) * | 1990-07-24 | 1992-01-25 | Gail W. Wertz | Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells |
| GB9200117D0 (en) * | 1992-01-06 | 1992-02-26 | Connaught Lab | Production of recombinant chimeric proteins for vaccine use |
| CA2136677A1 (en) * | 1993-12-29 | 1995-06-30 | Intervet, Inc. | Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv |
| EP1170368B1 (en) * | 1994-01-27 | 2010-07-28 | University Of Massachusetts Medical Center | Immunization by inoculation of dna transcription unit |
| US5541102A (en) * | 1994-09-02 | 1996-07-30 | Board Of Regents, University Of Nebraska-Lincoln | Bovine cell line resistant to in vitro infection by bovine viral diarrhea virus and all other known pestiviruses |
| US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US6060457A (en) | 1996-06-20 | 2000-05-09 | Universite De Montreal | DNA plasmid vaccine for immunization of animals against BVDV |
| FR2751229B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
| JP5566663B2 (ja) * | 2009-11-09 | 2014-08-06 | 三菱重工業株式会社 | 多翼遠心ファンおよびそれを用いた空気調和機 |
-
1996
- 1996-07-19 FR FR9609403A patent/FR2751229B1/fr not_active Expired - Lifetime
-
1997
- 1997-07-06 NZ NZ517686A patent/NZ517686A/xx not_active IP Right Cessation
- 1997-07-06 NZ NZ508940A patent/NZ508940A/xx not_active IP Right Cessation
- 1997-07-06 NZ NZ508939A patent/NZ508939A/en not_active IP Right Cessation
- 1997-07-11 AR ARP970103111A patent/AR007862A1/es active IP Right Grant
- 1997-07-15 HR HR9609403A patent/HRP970383A2/hr not_active Application Discontinuation
- 1997-07-16 BR BR9710506A patent/BR9710506A/pt not_active Application Discontinuation
- 1997-07-16 ZA ZA976283A patent/ZA976283B/xx unknown
- 1997-07-16 CZ CZ20070776A patent/CZ298915B6/cs not_active IP Right Cessation
- 1997-07-16 WO PCT/FR1997/001325 patent/WO1998003200A2/fr not_active Ceased
- 1997-07-16 AT AT97934578T patent/ATE253376T1/de active
- 1997-07-16 EP EP03016996A patent/EP1382348B1/fr not_active Expired - Lifetime
- 1997-07-16 UA UA99020960A patent/UA70914C2/uk unknown
- 1997-07-16 DE DE69734483T patent/DE69734483T2/de not_active Expired - Lifetime
- 1997-07-16 EP EP97934578A patent/EP0912194B1/fr not_active Expired - Lifetime
- 1997-07-16 MA MA24716A patent/MA24269A1/fr unknown
- 1997-07-16 IL IL12770397A patent/IL127703A0/xx active IP Right Grant
- 1997-07-16 NZ NZ333751A patent/NZ333751A/en not_active IP Right Cessation
- 1997-07-16 PL PL97331236A patent/PL190122B1/pl unknown
- 1997-07-16 HU HU9902791A patent/HU225169B1/hu unknown
- 1997-07-16 PT PT97934578T patent/PT912194E/pt unknown
- 1997-07-16 AU AU37735/97A patent/AU734442B2/en not_active Expired
- 1997-07-16 ES ES97934578T patent/ES2210548T3/es not_active Expired - Lifetime
- 1997-07-16 CA CA2260855A patent/CA2260855C/en not_active Expired - Lifetime
- 1997-07-16 DE DE69725988T patent/DE69725988T2/de not_active Expired - Lifetime
- 1997-07-16 ID IDP972480A patent/ID19513A/id unknown
- 1997-07-16 DK DK97934578T patent/DK0912194T3/da active
- 1997-07-16 ES ES03016996T patent/ES2254833T3/es not_active Expired - Lifetime
- 1997-07-16 CZ CZ0017599A patent/CZ298898B6/cs not_active IP Right Cessation
- 1997-07-16 DK DK03016996T patent/DK1382348T3/da active
- 1997-07-16 AT AT03016996T patent/ATE307607T1/de active
- 1997-07-16 JP JP09535655A patent/JP2000516200A/ja active Pending
- 1997-07-16 HU HU0500910A patent/HU228353B1/hu unknown
- 1997-07-17 AP APAP/P/1997/001044A patent/AP9701044A0/en unknown
- 1997-07-18 CO CO97040983A patent/CO4700306A1/es unknown
-
1998
- 1998-01-16 PE PE1998000035A patent/PE84699A1/es not_active Application Discontinuation
- 1998-12-23 IL IL127703A patent/IL127703A/en not_active IP Right Cessation
-
1999
- 1999-01-15 US US09/232,279 patent/US6376473B1/en not_active Expired - Lifetime
-
2002
- 2002-02-28 US US10/085,519 patent/US6818628B2/en not_active Expired - Lifetime
- 2002-12-05 RU RU2002132831/13A patent/RU2305560C2/ru active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA70914C2 (uk) | Вакцина для великої рогатої худоби проти респіраторних патологій, спосіб вакцинації та набір для вакцинації великої рогатої худоби | |
| KR100620302B1 (ko) | 개 질병, 특히 호흡기 및 소화성 질병 치료용폴리뉴클레오티드 백신 제제 | |
| RU2305559C2 (ru) | Вакцина свиней против респираторных патологий и патологий репродукции свиней | |
| JP2593295B2 (ja) | 組換え体表面タンパク質を持つウイルス | |
| CZ301365B6 (cs) | Imunogenní kompozice pro vyvolání u savce celedi konovitých imunologické odezvy proti viru rinopneumonitidy, použití této kompozice pro výrobu léciva a souprava obsahující tuto kompozici | |
| WO2012107614A1 (es) | Vacuna contra el virus de la peste porcina africana basada en virus recombinantes deficientes en replicación | |
| AU2025279721A1 (en) | Multivalent feline vaccine | |
| Plotkin | Vaccination in the 21st century | |
| Hsieh et al. | DNA-mediated vaccination conferring protection against infectious bursal disease in broiler chickens in the presence of maternal antibody | |
| CN116102660A (zh) | 一种猪细小病毒基因工程表位疫苗及其制备方法 | |
| US8465748B2 (en) | Vaccine compositions and methods containing an immunogen derived from equine arteritis virus | |
| US11730809B2 (en) | Multivalent feline vaccine | |
| RU2215035C2 (ru) | Рекомбинантный полиовирусный вектор (варианты), способ его получения (варианты), способ индукции иммунного ответа у индивидуума (варианты), способ получения белка (варианты), вакцинная композиция для терапии или профилактики инфекционных заболеваний (варианты) | |
| AU674134B2 (en) | Recombinant viruses comprising artificial proteolytic cleavage site | |
| RU2204599C1 (ru) | Штамм № 1734 "приморский-2000" вируса ящура типа о для изготовления диагностических и вакцинных препаратов | |
| EP2900685B1 (en) | Attenuated chikungunya virus | |
| EP3706790A1 (en) | Multivalent feline vaccine | |
| EP1346998A1 (en) | Equine arteritis virus vaccine | |
| Bohmer | Engineering of a chimeric SAT2 foot-and-mouth disease virus for vaccine production | |
| Seibutukagaku | V1RBA C | |
| Mukhopadhyay et al. | Review on Gene-Based Vaccines | |
| CN102008735A (zh) | 一种小分子dna疫苗及其制备方法 |